37 related articles for article (PubMed ID: 111465)
1. Ultrasound and magnetic resonance imaging-based investigation of the role of perfusion and oxygen availability in menstrual pain.
Cockrum RH; Tu FF; Kierzkowska O; Leloudas N; Pottumarthi PV; Hellman KM
Am J Obstet Gynecol; 2024 May; 230(5):553.e1-553.e14. PubMed ID: 38295969
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: A network meta-analysis.
Feng X; Wang X
Mol Pain; 2018; 14():1744806918770320. PubMed ID: 29587566
[TBL] [Abstract][Full Text] [Related]
3. The lack of efficacy of oxytocin and NSAIDs.
Agabio R; Mameli S; Melis MR
Rheumatol Int; 2015 May; 35(5):943-4. PubMed ID: 25588370
[No Abstract] [Full Text] [Related]
4. Endogenous prostaglandins in dysmenorrhea and the effect of prostaglandin synthetase inhibitors (PGSI) on uterine contractility.
Lundström V; Gréen K; Svanborg K
Acta Obstet Gynecol Scand Suppl; 1979; 87():51-6. PubMed ID: 111466
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of ibuprofen and naproxen sodium on menstrual prostaglandin release and on prostaglandin production in the rat uterine homogenate.
Powell AM; Chan WY
Prostaglandins Leukot Med; 1984 Feb; 13(2):129-37. PubMed ID: 6585839
[TBL] [Abstract][Full Text] [Related]
6. The effect of naproxen-sodium on the intrauterine pressure and menstrual pain of dysmenorrheic patients.
Csapo AI; Pulkkinen MO; Henzl MR
Prostaglandins; 1977 Jan; 13(1):193-9. PubMed ID: 320630
[TBL] [Abstract][Full Text] [Related]
7. The effect of naproxen-sodium on the prostaglandin concentrations of the menstrual blood and uterine "jet-washings" in dysmenorrheic women.
Pulkkinen MO; Henzl MR; Csapo AI
Prostaglandins; 1978 Mar; 15(3):543-50. PubMed ID: 351717
[No Abstract] [Full Text] [Related]
8. Suppression of uterine activity by prostaglandin synthetase inhibitors.
Pulkkinen MO
Acta Obstet Gynecol Scand Suppl; 1979; 87():39-43. PubMed ID: 111465
[TBL] [Abstract][Full Text] [Related]
9. A rationale for the treatment of dysmenorrhea.
Csapo AI
J Reprod Med; 1980 Oct; 25(4 Suppl):213-21. PubMed ID: 7001020
[TBL] [Abstract][Full Text] [Related]
10. Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations.
Dawood MY
Drugs; 1981 Jul; 22(1):42-56. PubMed ID: 6790261
[TBL] [Abstract][Full Text] [Related]
11. Current status of the etiology and management of dysmenorrhea in adolescence.
Alvin PE; Litt IF
Pediatrics; 1982 Oct; 70(4):516-25. PubMed ID: 6812011
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
